Kevin P. Starr

Co-Founder at Third Rock Ventures LLC

Kevin P. Starr

Kevin P. Starr

Co-Founder at Third Rock Ventures LLC

Overview
Career Highlights

Takeda Oncology Co.
Afferent Pharmaceuticals, Inc.
Decibel Therapeutics, Inc.

RelSci Relationships

2329

Number of Boards

12

Birthday

1963

Age

56

Relationships
RelSci Relationships are individuals Kevin P. Starr likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at SAGE Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Tal Medical, Inc.

Relationship likelihood: Strong

Venture Partner at 5AM Venture Management LLC

Relationship likelihood: Strong

Former Chief Financial Officer at Gilead Sciences, Inc.

Relationship likelihood: Strong

Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

President & Chief Executive Officer at PanOptica, Inc.

Relationship likelihood: Strong

Executive Chairman at Kaleido Biosciences, Inc.

Relationship likelihood: Strong

Co-Founder at Third Rock Ventures LLC

Relationship likelihood: Strong

Founding President & Chief Executive Officer at Revolution Medicines, Inc.

Relationship likelihood: Strong

Paths to Kevin P. Starr
Potential Connections via
Relationship Science
You
Kevin P. Starr
Co-Founder at Third Rock Ventures LLC
Education
BA Mathematics & Business

Colby College is a private liberal arts college located on Mayflower Hill in Waterville, Maine, USA. Founded in 1813, it is the 12th-oldest independent liberal arts college in the United States. Colby was the first all-male college in New England to accept female students in 1875.

M.S. in Corporate Finance

Boston College is one of the nation's best and most selective universities, with U.S. News & World Report ranking Boston College 31st among national universities, and Forbes ranking it 26th in its 2012 America's Best Colleges listing. Boston College confers more than 4,000 degrees annually in more than 50 fields of study through eight schools and colleges. Faculty members are committed to both teaching and research having earned nearly $60 million in research grants in the last year alone. The University has made a major commitment to academic excellence. As part of its Strategic Plan, Boston College is in the process of adding 100 new faculty positions, expanding faculty and graduate research, increasing student financial aid to more than $128 million annually, and widening opportunities in key undergraduate programs, such as international study, internships and student formation. Boston College has experienced tremendous growth in recent years, including a 75 percent increase in undergraduate applications over the past decade, to more than 34,000 for the 2,250 seats in its freshman class. During the same period, an increase in voluntary giving from alumni has helped to move the University's endowment to approximately $1.9 billion. Boston College students have also earned more than 200 prestigious academic scholarships over the past decade, including 2 Rhodes Scholarships, 4 Marshalls, 9 Goldwaters and 162 Fulbright grants.

Career History
Co-Founder
2007 - Current

Third Rock invests in early-stage product-focused life science companies, particularly biotechnology, biopharmaceutical and medical device companies. They look for companies with high-growth potential that are well-positioned to bring about change in the marketplace. The firm focuses on transformative life sciences companies in areas of disruptive science likely to make a difference in the lives of patients. Third Rock actively engages with their portfolio companies to provide hands-on support.

Chairman & Interim Chief Executive Officer
2015 - 2016

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair and restore hearing. It primarily focuses on hearing disorders, including noise-induced hearing loss; residual hearing preservation or improved sound fidelity with cochlear implants; presbycusis or age-related hearing loss; tinnitus, a persistent ringing in the ears; and genetic hearing loss. The firm also provides drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. The company was founded by Kevin Paul Starr, M. Charles Liberman, Gabriel Corfas, Ulrich Müller and Albert Edge in 2015 and is headquartered in Boston, MA.

Interim Chief Executive Officer
2011 - 2013

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Boards & Committees
Chairman of the Board
2011 - Current

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Member, Board of Directors
Current

PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ.

Chairman, Board of Directors
2015 - Prior

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The firm primarily focuses on hearing disorders, including noise-induced hearing loss; residual hearing preservation or improved sound fidelity with cochlear implants; presbycusis or age-related hearing loss; tinnitus, a persistent ringing in the ears; and genetic hearing loss. It also offers drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. The company was founded by Kevin Paul Starr, M. Charles Liberman, Gabriel Corfas, Ulrich Müller and Albert Edge in October 2015 and is headquartered in Boston, MA.

Political Donations
$2,500
2012

Senator from Washington

Transactions
Details Hidden

Merck & Co., Inc. purchases Afferent Pharmaceuticals, Inc. from Domain Associates LLC, Pappas Capital LLC, Roche Ventures, New Leaf Venture Partners LLC, Third Rock Ventures LLC

Details Hidden

Third Rock Ventures III LP raised money in a private placement transaction

Details Hidden

Third Rock Ventures II LP raised money in a private placement transaction

Investments
Details Hidden

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair and restore hearing. It primarily focuses on hearing disorders, including noise-induced hearing loss; residual hearing preservation or improved sound fidelity with cochlear implants; presbycusis or age-related hearing loss; tinnitus, a persistent ringing in the ears; and genetic hearing loss. The firm also provides drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. The company was founded by Kevin Paul Starr, M. Charles Liberman, Gabriel Corfas, Ulrich Müller and Albert Edge in 2015 and is headquartered in Boston, MA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Kevin P. Starr. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Kevin P. Starr's profile does not indicate a business or promotional relationship of any kind between RelSci and Kevin P. Starr.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/kevin-p-starr-3246189
  • https://relationshipscience.com/person/kevin-p-starr-3246189